Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals-Reference-Cited by-同舟云学术

Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals

Published:2021-11 Issue:5 Volume:58 Page:106439
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Castanheira Mariana^ORCID,Doyle Timothy B.,Deshpande Lalitagauri M.^ORCID,Mendes Rodrigo E.,Sader Helio S.

Funder

AbbVie Inc

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference32 articles.

1. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace;Logan;J Infect Dis,2017

2. Implementation manual to prevent and control the spread of carbapenem-resistant organisms at the national and health care facility level,2019

3. Infectious Disease Society of America guidance on the treatment of antimicrobial resistant Gram-negative infections,2020

4. US Centers for Disease Control and Prevention (CDC). Biggest threats and data. 2019 AR threats report. Atlanta, GA: CDC; 2019. https://www.cdc.gov/drugresistance/biggest-threats.html#carp [accessed 22 September 2021].

5. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients;Perez;Cleve Clin J Med,2013

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efflux pump-mediated resistance to new beta lactam antibiotics in multidrug-resistant gram-negative bacteria;Communications Medicine;2024-08-29

2. An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients;Journal of Antimicrobial Chemotherapy;2024-08-19

3. In vitro activity of ceftazidime-avibactam against gram-negative bacteria in patients with bacteremia and skin and soft-tissue infections in Colombia 2019–2021;Diagnostic Microbiology and Infectious Disease;2024-06

4. Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance;The Lancet;2024-06

5. Global phylogeography and genomic characterization of blaKPC and blaNDM-positive clinical Klebsiella aerogenes isolates from China, 2016-2022;Science of The Total Environment;2024-05